anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Recurrent mutations in isocitrate dehydrogenase 1 (mIDH1) occur in about 7% to 14% of all cases of acute myeloid leukemia (AML). The discovery of targetable mutations in AML, including IDH mutations, expanded the therapeutic landscape of AML and led to the development of targeted agents. Despite significant advances in current treatment options, remission and overall survival rates remain suboptimal. The IDH1 inhibitor, olutasidenib, demonstrated encouraging safety and clinical benefits as monotherapy in patients with relapsed or refractory (R/R) mIDH1 AML.
AREAS COVERED: This review outlines the olutasidenib drug profile and summarizes key safety and efficacy data, focusing on the 150 mg twice daily dose from the pivotal registrational cohort of the phase 2 trial that formed the basis for the US Food and Drug Administration approval of olutasidenib in patients with R/R AML with a susceptible IDH1 mutation.
EXPERT OPINION: Olutasidenib offers patients with R/R mIDH1 AML a new treatment option, with improved complete remission and a longer duration of response than other targeted mIDH1 treatment options. Olutasidenib provided clinical benefit with a manageable safety profile. Additional analyses to further characterize the safety and efficacy of olutasidenib in frontline and R/R settings as monotherapy and as combination therapy are ongoing.
The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders. Voltage-gated sodium channels (NaVs) are responsible for action potential initiation and transmission of pain signals. NaV1.8 is specifically expressed in peripheral nociceptors and has been genetically and pharmacologically validated as a human pain target. Selective inhibition of NaV1.8 can ameliorate pain while minimizing effects on other NaV isoforms essential for cardiac, respiratory, and central nervous system physiology. Here we present the pharmacology, interaction site, and mechanism of action of LTGO-33, a novel NaV1.8 small molecule inhibitor. LTGO-33 inhibited NaV1.8 in the nM potency range and exhibited over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. Unlike prior reported NaV1.8 inhibitors that preferentially interacted with an inactivated state via the pore region, LTGO-33 was state-independent with similar potencies against closed and inactivated channels. LTGO-33 displayed species specificity for primate NaV1.8 over dog and rodent NaV1.8 and inhibited action potential firing in human dorsal root ganglia neurons. Using chimeras combined with mutagenesis, the extracellular cleft of the second voltage-sensing domain was identified as the key site required for channel inhibition. Biophysical mechanism of action studies demonstrated that LTGO-33 inhibition was relieved by membrane depolarization, suggesting the molecule stabilized the deactivated state to prevent channel opening. LTGO-33 equally inhibited wild-type and multiple NaV1.8 variants associated with human pain disorders. These collective results illustrate LTGO-33 inhibition via both a novel interaction site and mechanism of action previously undescribed in NaV1.8 small molecule pharmacologic space. SIGNIFICANCE STATEMENT: NaV1.8 sodium channels primarily expressed in peripheral pain-sensing neurons represent a validated target for the development of novel analgesics. Here we present the selective small molecule NaV1.8 inhibitor LTGO-33 that interdicts a distinct site in a voltage-sensor domain to inhibit channel opening. These results inform the development of new analgesics for pain disorders.
Prior to analyzing continuous variables, the statistical normality of the data will be determined. The differences between the main variables will be compared by using the analysis of variance. A comparison of data on categorical variables will be carried out by χ2 tests or Fisher's exact tests. The OS and PFS was estimated using the Kaplan-Meier method. PFS and OS will be compared using the log-rank test. In cases where variables must be adjusted, we will use the proportional hazard Cox regression model. P values for all analyses will be based on using a significance level of 0.05.
The primary aim of this study is to determine if zinc supplementation improves bone health in young patients with thalassemia. Osteoporosis is a significant co-morbidity in patients with thalassemia which leads to decreased quality of life. The most effective way to prevent osteoporosis is to build strong, dense bones in the early years. A combination of disease, endocrine and nutritional factors likely contribute to the etiology of osteoporosis in this population. However, even well transfused patients with normal gonadal function who are supplemented with calcium have low bone mass. It is hypothesized that patients with thalassemia have low bone mass, in part, due to zinc deficiency. Sub-optimal zinc status has been identified in patients with thalassemia and zinc supplementation has been shown to improve linear growth. To test the primary hypothesis, an 18 month randomized placebo-controlled trial of zinc supplementation (25 mg Zn/day) vs. placebo will be conducted in 60 young patients (6-30 yrs) with thalassemia and low bone mass (spine BMD Z-score \<-1.0). Bone health, as estimated from measurements of bone mass (by DXA and pQCT) and markers of bone formation and resorption will be the primary outcome variables. This will be the first study to examine the effects of zinc. supplementation on bone health in patients with thalassemia. If zinc supplementation is found to have a clinically important effect, this simple, safe, non-invasive therapy could quickly become a part of the standard care of these young patients and improve overall health in children and adult patients with thalassemia
HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
Sepsis, a critical health condition induced by an overactive innate immune response and reactive oxygen species (ROS)-driven host damage through apoptosis and ferroptosis, continues to pose a significant mortality risk. Despite accumulating evidence of the potential therapeutic properties of tea ingredients, their specific anti-sepsis potential remains inadequately explored. This study comprehensively investigates the targeted genes of tea ingredients, notably epigallocatechin 3-gallate (EGCG), and their correlation with sepsis signature genes. Our findings elucidate that tea ingredients, especially EGCG, exhibit substantial potential in mitigating inflammation and sepsis-induced damage. Through the inhibition of the MAPK cascade and macrophage activation and by impeding the transcriptional activity of RELA (transcription factor p65) in sepsis, EGCG demonstrates significant anti-sepsis efficacy. Molecular docking analysis further underpins this by revealing the close proximity of EGCG and (-)-catechin gallate binding sites to that of RELA on DNA. Subsequent in vitro assays illuminated EGCG's instrumental role in modulating macrophage M2 polarization, balancing M1 and M2 differentiation of bone marrow-derived macrophages (BMDMs), curtailing inflammatory factor secretion, and inhibiting ROS production. Moreover, EGCG effectively suppresses the expression of ferroptosis/apoptosis markers in LPS-induced macrophages during their early stages. Our study advances our understanding of sepsis prevention and treatment strategies, suggesting that tea ingredients such as EGCG could play a pivotal role in developing future sepsis therapies due to their protective effects.
The case-cohort design obtains complete covariate data only on cases and on a random sample (the subcohort) of the entire cohort. Subsequent publications described the use of stratification and weight calibration to increase efficiency of estimates of Cox model log-relative hazards, and there has been some work estimating pure risk. Yet there are few examples of these options in the medical literature, and we could not find programs currently online to analyze these various options. We therefore present a unified approach and R software to facilitate such analyses. We used influence functions adapted to the various design and analysis options together with variance calculations that take the two-phase sampling into account. This work clarifies when the widely used "robust" variance estimate of Barlow (Biometrics 50:1064-1072, 1994) is appropriate. The corresponding R software, CaseCohortCoxSurvival, facilitates analysis with and without stratification and/or weight calibration, for subcohort sampling with or without replacement. We also allow for phase-two data to be missing at random for stratified designs. We provide inference not only for log-relative hazards in the Cox model, but also for cumulative baseline hazards and covariate-specific pure risks. We hope these calculations and software will promote wider use of more efficient and principled design and analysis options for case-cohort studies.
Participants will receive AZD0486 as intravenous (IV) infusion in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy as per standard of care. For participants achieving CR or PR, AZD0486 will be administered every 3 weeks.
Prior to each 2-week treatment phase, subjects will complete a 1-week washout period. Following the washout period, the intra-oral appliance containing a donorMIH tooth block will be fitted to each subject by a qualified dentist. Immediately after fitting of the first appliance (on day 1 of the first treatment phase), each subject will receive a soft bristled manual toothbrush for use throughout the duration of the study and a toothpaste according to the treatment phase. Subjects will be instructed to brush their teeth with the appliance in the mouth, two times daily, for 3 minutes on each brushing episode, in the morning after breakfast and last thing before bed, then rinsing with 10 ml of water. Over the study period, all subjects will maintain their normal dietary habits.

A 7-day washout period without an appliance will follow. After completion of the second washout period, subjects will return to the clinic, and the appliance, with another MIH-bearing tooth blocks mounted, will be fitted to the subject for the phase 2 treatment period. This procedure will then be repeated until the 2-week treatment phase is completed, and each subject has gone through the two arms of the study.
The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
The present invention provides methods of improving cognitive function, e.g., at least one of situational memory, executive function, or language skill; support memory and/or recall; providing energy and/or ketones to the brain; and/or preventing and/or treating Mild Cognitive Impairment (MCI) in an individual. A composition comprising Medium Chain Triglycerides (MCTs) can be administered to an individual in a daily dose that provides about 15g to about 45g MCTs. The MCT can comprise from about 51 wt% to about 90 wt% caprylic acid. The daily dose may be provided in at least two parts, for example 2 or 3 parts. Each serving may provide about 15g MCT and may contain caprylic acid and capric acid, for example, in a weight ratio of about 60: about 40. The individual may be 65 years old or older and/or have Mild Cognitive Impairment (MCI).
A method for calculating a high risk route of administration is provided. Multiple arrangement routes composed of every two medicines among multiple medicines included in a medical record database (121) are listed (S205). A risk value of each arrangement route is calculated by querying the medical record database (121) based on a specified medication result (S210). A risk score of each arrangement route is calculated according to the risk value, and the arrangement routes are sorted based on the risk scores (S215). Starting from the arrangement route with the highest risk score, N arrangement routes are retrieved and a combination on N of the arrangement routes is performed to obtain multiple strung routes (S220). The number of medicines included in each strung route matches a specified medication number.
The invention relates to lactobacillus plantarum HL-16 and application thereof, belonging to the technical field of microorganisms. The lactobacillus plantarum HL-16 is obtained by separating and screening chicken manure, is lactobacillus, is preserved and has the preservation number of CGMCC No. 24035. The biological characteristic analysis of the lactobacillus plantarum HL-16 shows that the lactobacillus plantarum has the advantages of good tolerance, strong acid production capacity, high level of produced beta-glucosidase, high growth speed and the like, can be used for performing bacterium-enzyme synergistic fermentation with saccharomyces cerevisiae and cellulase, is applied to solid-state fermentation traditional Chinese medicines, and the fermented traditional Chinese medicines have good antibacterial performance. The invention mainly uses the strains with independent intellectual property rights to ferment the traditional Chinese medicine, greatly improves the release of physiologically active substances in the traditional Chinese medicine, and obviously inhibits the growth and reproduction of pathogenic bacteria, thereby avoiding the generation of harmful metabolites and having the function of promoting the growth of animals. The lactobacillus plantarum HL-16 is an excellent probiotic.
Hyperlipidemic acute pancreatitis (HAP) is a serious inflammatory pancreatic disease commonly seen in patients with disorders of lipid metabolism. Decreasing blood triglyceride levels and proinflammatory factors can alleviate hyperlipidemic pancreatitis. The lipase that enhanced the Brownian motion of mesoporous silica in triglyceride solutions could accelerate decomposition of the lipid and improve the efficiency of absorption. In this study, we developed a mesoporous silica nanoparticle with dual modification of IL-6 aptamer and lipase for the treatment of HAP. The nanoparticle could increase the ability of particles to absorb inflammatory factor IL-6 and decompose triglycerides. For every 10 mg of the dual-modified nanoparticles, the efficiency of capturing IL-6 was approximately 9.67 pg/mL and of decomposing triglycerides was approximately 3.88 mg/mL in the plasma of HAP patients within 2 h. In summary, the mesoporous silica nanoparticle could absorb the IL-6 inflammatory factor through IL-6 aptamers and decompose triglycerides through lipase. Furthermore, based on clinically available plasma exchange technology, combined with our developed dual-modified nanoparticles, we designed an absorption device for the treatment of hyperlipidemic pancreatitis; it works to promote the treatment of hyperlipidemic pancreatitis.
The present invention provides a prostaglandin E1 nano particle administration system for intravenous injection which comprises prostaglandin E1 with effective treatment dose, polyethyleneglycol derivatization phosphatide and an auxiliary agent, wherein the auxiliary agent can be accepted in pharmacy. A medicament is coated in the formed nano particles, and thus, a prostaglandin E1 administration system for injecting is prepared. The nano particle administration system of the present invention can be in forms of liposomes, microemulsion, micelles or a mixture thereof. After the nano particles are formed, polyethyleneglycol long chains can be distributed on the surfaces of the nano particles to form a hydrophilic protective film. On one hand, the hydrophilic protective film prevents the mutual aggregation among the nano particles; on the other hand, the hydrophilic protective film can avoid the medicines being identified and phagocytized by an in vivo reticuloendothelial system, and prolong the retention time of the nano particle administration system in the blood circulation. In addition, the medicament is coated in hydrophobic cores, the medicament is free from the damage of external factors (water, oxygen and light), and the stability of the medicament in the storage process is greatly enhanced.
we will conduct a single-center, single-group prospective study with safety and imaging endpoints. A total of 10 KD children or young adults with indication of revascularization are enrolled, and BVS will be implanted for stenotic or occluded lesions. QCA and optical coherence tomography (OCT) are used to evaluate the baseline lumen area, plaque characteristics, and BVS expansion or eccentricity after deployment. At 12 months, scaffold restenosis is evaluated by multislice computed tomography. At 30 months, patients will receive follow-up by angiography and OCT to evaluate lumen area, neoplaque characteristics, and side branch conditions. Otherwise, the composite endpoint including cardiac death, myocardial infarction, and ischaemia-driven target lesion revascularisation are assessed at 30 days, 6 and 9 months, and 1, 2, 3 years.
BACKGROUND: Hyperekplexia is a rare neurogenetic disorder that is classically characterized by an exaggerated startle response to sudden unexpected stimuli. This study aimed to determine clinical and genetic characteristics of our patients with hyperekplexia.
METHODS: The age of onset and diagnosis, familial and perinatal history, clinical course, complications, metabolic screening tests, magnetic resonance imaging (MRI), medications, neuropsychometric evaluations, and gene mutations of patients diagnosed with hyperekplexia were reviewed retrospectively.
RESULTS: All hyperekplexia patients had displayed neonatal excessive startle response and muscle stiffness, which we accepted as the major form of the disorder. Sixteen patients had mutations in genes associated with hyperekplexia. The ages at clinical diagnosis and genetic confirmation ranged from newborn to 16 years old and from 2.5 to 19 years, respectively. Nine patients (56.25%) were initially misdiagnosed with epilepsy. Seven patients (43.75%) carried a diagnosis of intellectual disability, defined here as a total IQ <80. Delayed gross motor development was detected in 4 patients (25%), and speech delay was reported in 3 (18.75%). Mutations in GLRA1 (NM_000171.4) and SLC6A5 (NM_004211.5) were identified in 13 (81.25%) and 3 patients (18.75%), respectively. Fifteen of the 16 patients (93.75%) showed autosomal recessive inheritance. Only 1 patient (6.25%) showed autosomal dominant inheritance.
CONCLUSION: Although hyperekplexia is a potentially treatable disease, it can be complicated by delayed speech and/or motor acquisition and also by intellectual disability. This study shows that hyperekplexia is not always a benign condition and that all patients diagnosed with hyperekplexia should be evaluated for neuropsychiatric status and provided with genetic testing.
Methods and compositions for treating skin ailments are described herein. Embodiments of the invention include a therapeutic composition. The thereapeutic composition is adapted for cleansing and treating skin and further includes an emu oil based composition. The emu oil based composition includes from about 20 wt. % to about 75 wt. % of refined sterilized emu oil, from about 0.01 wt. % to about 33 wt. % of one or more aromatic alcohols, from about 10 wt. % to about 25 wt. % of one or more benzoic acids, from about 0.2 wt. % to about 2.0 wt. % of allantoin, from about 0.025 wt. % to about 1.25 wt. % of methylparaben, from about 1.0 wt. % to about 13.0 wt. % of one or more alkyl esters and from about 0.01 wt. % to about 0.30 wt. % of propylparaben. Embodiments of the invention further include a composition including an aqeous emu oil based composition, wherein the aqueous emu oil based composition is adapted for cleansing and treating skin. Embodiments of the invention further include an absorbent article. The absorbent article includes a liquid permeable top sheet, wherein the liquid permeable top sheet is adapted to contact skin and is treated with an emu oil based composition. The absorbent article further includes a liquid permeable back sheet and an absorbent core disposed between the liquid permeable top sheet and the liquid permeable back sheet. Embodiments of the invention further include a method for preventing baby rashes and skin ailments. The method includes preparing an emu oil based composition and applying the emu oil based composition to an ailment selected from the group including baby rashes and skin ailments.
The invention belongs to an oral Chinese herbal preparation for treating post-traumatic brain syndrome, and the oral Chinese herbal preparation is a human medicinal product. The preparation is prepared from the following Chinese herbs in parts by weight: 10+/-2 parts of Astragalus mongholicus, 10+/-2 parts of American ginseng, 10+/-2 parts of Angelica sinensis, 10+/-2 parts of medlar, 10+/-2 parts of the root of red-rooted salvia, 10+/-2 parts of ligusticum wallichii, 10+/-2 parts of root of common peony, 10+/-2 parts of peach kernel, 10+/-2 parts of Poria cocos, 10+/-2 parts of pericarpium citri reticulatae, 10+/-2 parts of plantain seed, 10+/-2 parts of tabasheer, 10+/-2 parts of rhizoma acori graminei, 10+/-2 parts of gastrodia elata, 10+/-2 parts of uncaria, 10+/-2 parts of spina date seed, 10+/-2 parts of amber powder and 6+/-1.2 parts of honey-fried licorice root. Clinical effect observation proves that the total effective rate of the oral Chinese herbal preparation to the oral traditional Chinese medicine preparation is 94.07%, and has better treatment effect (P<0.01) compared with Western medicines such as Rotundine, piracetam, oryzanol and nimodipine for treating post-traumatic brain syndrome. Moreover, the Chinese herbal preparation has no obvious toxic or side effect, and can be taken for a long time. The dose of the preparation is small, and effective medicinal components are easy to release, can be absorbed quickly and can fully play the pharmaceutical effect. The preparation is convenient to carry, easy to take and beneficial to large-scale production.